ClinicalTrials.gg
RecruitingNCT07631052Updated Aug 18, 2026

Capecitabine in ER+/HER2-negative Breast Cancer

A Phase 2 interventional study of Capecitabine in ER-positive, HER2-negative Breast Cancer, Breast Cancer Stage I and Breast Cancer Stage II, sponsored by University Health Network, Toronto. Recruiting at 1 site in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-18.

Sponsored by University Health Network, Toronto · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jul 2026; still recruiting 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
15
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 233 studies testing capecitabine in Breast Neoplasms — 32 open to participants now, 41 under way, 10 of them phase 3. Capecitabine · Breast Neoplasms.

Planned enrollment
195th of 227
15 · median 54
Started
2026
with 4 others
Phase 2
121 of 233
20 open now
Primary completion
2029-08
later than 34 of 40 live
Registered
230th of 233
by date

Among the 233 studies testing capecitabine in Breast Neoplasms, this one is the 195th largest by planned enrollment of the 227 interventional ones that give a count, is one of 5 that started in 2026, is one of 121 in phase 2, reaches primary completion later than 34 of the 40 other live ones, and was the 230th registered.

Breast Neoplasms

14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

32 of the 233 studies testing capecitabine in Breast Neoplasms are open now, in 5 countries. Recruiting first, the newest first:

26 more — sign in →

By country, each count listing its studies:

All 32 open studies →

About capecitabine

Capecitabine: first FDA approval 1998 (XELODA), first EMA approval 2001. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 233 studies testing capecitabine in Breast Neoplasms, or all of them as a file.
02

Study summary

This is a Phase 2 study for patients with resected Stage I-III HR+/HER2-negative breast cancer with detected molecular residual disease (MRD+) following standard neo/adjuvant and locoregional therapy delivered with curative intent. In this study participants will be treated with capecitabine. Capecitabine will be administered orally at a dose of 500 mg 3 times daily for up to 12 months, or until the time of clinical recurrence, discontinuation due to toxicity, or withdrawal of consent. This study will have two stages, stage 1 would enroll up to 8 participants to clear the Minimal Residual Disease (MRD) and Stage 2 will enroll up to 5 participants. The purpose of this study is to determine if this study population would have a better outcome from receiving capecitabine rather than having no change in treatment if MRD is detected.

03

Conditions studied

  • ER-positive, HER2-negative Breast Cancer
  • Breast Cancer Stage I
  • Breast Cancer Stage II
  • Breast Cancer Stage III

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female patients ≥ 18 years of age with confirmed (by local assessment with ASCO/CAP criteria), resected ER-positive/-negative stage I-III breast cancer
  • Evidence of MRD (positive test by the Pathlight assay) despite standard therapy
  • No to capecitabine (including absence of DPYD variants that in the opinion of the investigator are a contraindication to metronomic capecitabine)
  • No clinical or radiographic evidence of recurrent or disease
  • Previous Therapy requirements: (i) Received at least 24 months of adjuvant endocrine therapy, including 6 months of an aromatase inhibitor and (i) Received at least 12 months of adjuvant CDK4/6i if indicated, unless not tolerated or declined
  • performance status of 0-1.
  • Patient must have adequate organ function as determined by the following:

    a. Renal function:

  • Serum creatinine \< 1.5 x (upper limit of normal range) or a calculated of > 50mL/min using the Cockcroft-Gault formula

    b. Bone marrow function (without hematopoietic growth factors or transfusion):

  • (ANC) > 1.0 x 109/L
  • > 90 g/L or > 9g/dL
  • > 75 x 109/L

    c. Liver function:

  • Total ≤ 1.5 × ULN and \< 35 uMol/L; OR total bilirubin >1.5 × ULN with indirect bilirubin \< 1.5 × ULN.
  • (AST/SGOT) and alanine aminotransferase (ALT/SGPT) \< 2.5 x ULN.
  • Female participants of must have a negative serum β-HCG test result at enrolment.
  • Female participants of childbearing potential must agree to use methods of that are highly effective.
  • Male participants must agree to use methods of contraception that are highly effective.
  • The participant is willing and able to comply with the protocol for the duration of the study including undergoing treatment and scheduled visits and examinations including follow up.
  • Signed written and voluntary .

Exclusion criteria

Exclusion Criteria:

  • Prior therapy with capecitabine.
  • Previous or concurrent within 3 years of study entry, with the following exceptions: adequately treated basal or squamous cell skin cancer, superficial bladder cancer, prostate intraepithelial neoplasm, carcinoma in-situ of the cervix, or other non-invasive or indolent malignancy; other solid tumors treated curatively without evidence of recurrence for at least 3 years prior to study entry.
  • Impaired cardiovascular function or cardiovascular diseases, including any of the following:

    1. History of acute coronary syndromes (including myocardial infarction, unstable angina, coronary artery bypass grafting, coronary angioplasty, or stenting) \<6 months prior to screening,
    2. Symptomatic chronic heart failure (e.g., Class ≥ 2), history or current evidence of clinically significant cardiac arrhythmia and/or conduction abnormality \<6 months prior to screening except atrial fibrillation and paroxysmal supraventricular tachycardia.
    3. Uncontrolled hypertension defined as persistent elevation of systolic blood pressure ≥ 160 mmHg or diastolic blood pressure ≥ 100mmHg, despite current therapy.
  • Known positive serology for (Human immunodeficiency virus) that is not currently controlled with antiretroviral therapy.
  • Has a known history of or is positive for active or unless adequate viral suppression is achieved. Participants who have had definitive treatment for HCV are permitted if HCV RNA is undetectable at Screening Visit.
  • Impaired gastrointestinal function or disease that may significantly alter the absorption of capecitabine.
  • Medical, psychiatric, cognitive, or other conditions that may compromise the patient's ability to understand the patient information, give , comply with the study protocol, or complete the study.
Terms in these criteria, in plain language(22)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
15 participants (estimated)

Study arms

  • Experimental
    Capecitabine

    Capecitabine 500 mg

    Drug: Capecitabine

Interventions

06

What researchers measure

Primary outcomes

  1. Clearance rate of ctDNA at 16 weeks after the use of metronomic capecitabine measured using the Pathlight assay in patients with molecular residual disease (MRD). ctDNA clearance is defined as no detection of plasma ctDNA.

    Time frame: Following Week 16 of treatment

Secondary outcomes

  1. Distant recurrence free survival (DRFS).

    Describe clinical outcomes for MRD+ patients treated with this escalated strategy, including distant recurrence free survival (DRFS).

    Time frame: Time of consent signed through to follow up (up to 5 years)

  2. Number and severity of treatment related adverse events as assessed by CTCAE v5.0.

    Time frame: Time of consent signed through to 30 days last dose of study drug

  3. Measure ctDNA levels in MRD positive patients using the Pathlight assay after initiation of metronomic capecitabine.

    Time frame: Time of consent signed through study completion, approximately 3 years

Other outcomes

  1. Number of patients with detectable residual disease and early treatment response using novel liquid biopsy.

    Time frame: Through study completion, approximately 3 years.

  2. Proportion of patients with ctDNA clearance (defined as undetectable by the tumor-informed personalized ctDNA assay) and log-fold change in ctDNA quantification.

    Proportion of patients with ctDNA clearance (defined as undetectable by the tumor-informed personalized ctDNA assay) and log-fold change in ctDNA quantification from baseline, stratified by tumor genomic features (somatic mutations, structural variants, and copy number alterations identified by whole-genome sequencing of tumor tissue), following capecitabine initiation in patients with molecular residual disease (MRD), in order to identify molecular determinants of ctDNA response.

    Time frame: Through study completion, approximately 3 years

  3. Frequency of tumor genomic alterations associated with subsequent development of ctDNA-detected molecular residual disease and treatment resistance during adjuvant surveillance and intervention in patients with primary ER+/HER2- breast cancer.

    Frequency of tumor genomic alterations (somatic mutations, structural variants, and copy number alterations identified by whole-genome sequencing of primary tumor tissue) associated with subsequent development of ctDNA-detected molecular residual disease (MRD) and treatment resistance (defined as ctDNA non-clearance or recurrence on tumor-informed personalized ctDNA assay) during adjuvant surveillance and intervention in patients with primary ER+/HER2- breast cancer.

    Time frame: Through study completion, approximately 3 years

  4. Type of tumor genomic alterations associated with subsequent development of ctDNA-detected molecular residual disease and treatment resistance during adjuvant surveillance and intervention in patients with primary ER+/HER2- breast cancer.

    Type of tumor genomic alterations (somatic mutations, structural variants, and copy number alterations identified by whole-genome sequencing of primary tumor tissue) associated with subsequent development of ctDNA-detected molecular residual disease (MRD) and treatment resistance (defined as ctDNA non-clearance or recurrence on tumor-informed personalized ctDNA assay) during adjuvant surveillance and intervention in patients with primary ER+/HER2- breast cancer.

    Time frame: Through study completion, approximately 3 years

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2026 (actual). Primary completion is estimated for Aug 2029, 36 months after the start.

Of 1,070 non-industry phase 2 interventional studies under Breast Neoplasms, half reached primary completion within 56 months of starting (the median), counting those still running; a quarter within 34 and three quarters within 89. This study's planned 36 months is below that.

Counting every sponsor, half of 1,302 studies reached it within 51 months; a quarter within 30 and three quarters within 83.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 4, 2025
First posted
Jun 5, 2026
StartActual
Jul 29, 2026
Primary completionEst.
Aug 1, 2029
CompletionEst.
Aug 1, 2029
Last update
Aug 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 18, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07631052
Responsible party
Sponsor
First posted
Jun 5, 2026
Start date
Jul 29, 2026
Primary completion
Aug 1, 2029 (estimated)
Completion
Aug 1, 2029 (estimated)
Last update
Aug 18, 2026

Study contacts

David Cescon, MD
Contact
dave.cescon@uhn.ca
416-946-2245

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Capecitabine

Start the discussion